|
|
Analysis of Oncolytic Virus Market and R&D Pattern |
HAN Jia,FAN Yue-lei,MAO Kai-yun**() |
Shanghai Information Center for Life Sciences, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 200031, China |
|
|
Abstract Oncolytic viruses, capable of infecting and destroying malignant tissues, are becoming new biological therapies for treating cancers. Their ability in selectively replicating inside cancer cells and inducing lysis of certain cancer cells leads to the releasing of tumor-specific antigens for anti-cancer immune responses, acting as in situ cancer vaccines. The insights into the mechanisms of virus replication, entry, induction and inhibition of immune response have promoted the technology development of virus utilization in the treatment of certain human diseases. In the past decade, the progress of clinical trials in the field of oncolytic viruses has confirmed the therapeutic benefits in cancer therpy. Using oncolytic virus as a carrier of foreign genes to treat specific types of cancer is a feasible method, which could become new growth avenue of the cancer immunotherapy market. This article provides a comprehensive and multidimensional analysis of the niche areas and the dynamic changes from several aspects such as the oncolytic virus immunotherapy market, key technology progress, major enterprise competition pattern and product R&D progress, combined with a forecast of the prospects for the development of oncolytic viruses as a cancer therapy, for the purpose of providing reference in research and development direction selection and regional industrial decision-making for related companies.
|
Received: 09 January 2023
Published: 04 July 2023
|
|
|
|
[1] |
Kelly E, Russell S J. History of oncolytic viruses: genesis to genetic engineering. Molecular Therapy, 2007, 15(4): 651-659.
doi: 10.1038/sj.mt.6300108
pmid: 17299401
|
|
|
[2] |
Vellinga J, Van der Heijdt S, Hoeben R C. The adenovirus capsid: major progress in minor proteins. Journal of General Virology, 2005, 86(6): 1581-1588.
doi: 10.1099/vir.0.80877-0
|
|
|
[3] |
Arnberg N. Adenovirus receptors: implications for targeting of viral vectors. Trends in Pharmacological Sciences, 2012, 33(8): 442-448.
doi: 10.1016/j.tips.2012.04.005
pmid: 22621975
|
|
|
[4] |
Dai M H, Zamarin D, Gao S P, et al. Synergistic action of oncolytic Herpes simplex virus and radiotherapy in pancreatic cancer cell lines. The British Journal of Surgery, 2010, 97(9): 1385-1394.
doi: 10.1002/bjs.7124
|
|
|
[5] |
De Clercq E. Antiviral drugs in current clinical use. Journal of Clinical Virology, 2004, 30(2): 115-133.
doi: 10.1016/j.jcv.2004.02.009
pmid: 15125867
|
|
|
[6] |
Diefenbach R, Sokolowski N, Rizos H. Oncolytic virotherapy using Herpes simplex virus: how far have we come? Oncolytic Virotherapy, 2015, 4: 207-219.
doi: 10.2147/OV.S66086
pmid: 27512683
|
|
|
[7] |
Chhikara B S, Parang K. Global cancer statistics 2022: the trends projection analysis. Chemical Biology Letters, 2023, 10(1): 451-451.
|
|
|
[8] |
Nabors L B, Portnow J, Ammirati M, et al. Central nervous system cancers, version 1.2015. Journal of the National Comprehensive Cancer Network, 2015, 13(10): 1191-1202.
doi: 10.6004/jnccn.2015.0148
pmid: 26483059
|
|
|
[9] |
Corrado G, Salutari V, Palluzzi E, et al. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Review of Anticancer Therapy, 2017, 17(12): 1147-1158.
doi: 10.1080/14737140.2017.1398088
pmid: 29086618
|
|
|
[10] |
Casali P G. Adjuvant chemotherapy for soft tissue sarcoma. American Society of Clinical Oncology Educational Book, 2015(35): e629-e633.
|
|
|
[11] |
Flaig T W, Spiess P E, Agarwal N, et al., Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2020, 18(3): 329-354.
doi: 10.6004/jnccn.2020.0011
|
|
|
[12] |
Feola S, Russo S, Ylösmäki E, et al. Oncolytic ImmunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment. Pharmacology & Therapeutics, 2022, 236: 108103.
|
|
|
[13] |
Puzanov I, Milhem M, Minor D, et al. Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol, 2016, 34(22): 2619-2626.
doi: 10.1200/JCO.2016.67.1529
pmid: 27298410
|
|
|
[14] |
Chesney Jason A, Antoni R, Long Georgina V, et al. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. Journal of Clinical Oncology, 2023, 41(3): 528-540.
|
|
|
[15] |
Gujar S, Bell J, Diallo J S. SnapShot: cancer immunotherapy with oncolytic viruses. Cell, 2019, 176(5): 1240-1240.e1.
doi: S0092-8674(19)30114-X
pmid: 30794777
|
|
|
[16] |
Twumasi-Boateng K, Pettigrew J L, Eunice Kwok Y Y, et al. Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer, 2018, 18(7): 419-432.
doi: 10.1038/s41568-018-0009-4
pmid: 29695749
|
|
|
[17] |
Wan P K T, Ryan A J, Seymour L W. Beyond cancer cells: targeting the tumor microenvironment with gene therapy and armed oncolytic virus. Molecular Therapy, 2021, 29(5): 1668-1682.
doi: 10.1016/j.ymthe.2021.04.015
|
|
|
[18] |
Pol J G, Workenhe S T, Konda P, et al. Cytokines in oncolytic virotherapy. Cytokine & Growth Factor Reviews, 2020, 56: 4-27.
|
|
|
[19] |
Jiang H, Shin D, Nguyen T T, et al. Localized treatment with oncolytic adenovirus delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas. Clinical Cancer Research, 2019, 25: 6801-6814.
doi: 10.1158/1078-0432.CCR-19-0405
pmid: 31455679
|
|
|
[20] |
Passaro C, Alayo Q, De Laura I, et al., Arming an oncolytic Herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy. Clin Cancer Res, 2019, 25(1): 290-299.
doi: 10.1158/1078-0432.CCR-18-2311
|
|
|
[21] |
Su Y H, Su C Q, Qin L X. Current landscape and perspective of oncolytic viruses and their combination therapies. Translational Oncology, 2022, 25: 101530.
doi: 10.1016/j.tranon.2022.101530
|
|
|
[22] |
Maroun J, Muñoz-Alía M, Ammayappan A, et al. Designing and building oncolytic viruses. Future Virology, 2017, 12(4): 193-213.
doi: 10.2217/fvl-2016-0129
pmid: 29387140
|
|
|
[23] |
Liu B L, Robinson M, Han Z Q, et al. ICP34.5 deleted Herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 2003, 10(4): 292-303.
doi: 10.1038/sj.gt.3301885
pmid: 12595888
|
|
|
[24] |
Andtbacka R H, Kaufman H L, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 2015, 33(25): 2780-2788.
doi: 10.1200/JCO.2014.58.3377
pmid: 26014293
|
|
|
[25] |
Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Current Cancer Drug Targets, 2018, 18(2): 171-176.
doi: 10.2174/1568009618666171129221503
|
|
|
[26] |
Chan W M, McFadden G. Oncolytic poxviruses. Annual Review of Virology, 2014, 1: 191-214.
doi: 10.1146/virology.2014.1.issue-1
|
|
|
[27] |
Zhang Q, Zhang J W, Tian Y F, et al. Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki 67 core promoter and armed with IL-15 against glioblastoma cells. Cell Biosci, 2020, 10: 124.
doi: 10.1186/s13578-020-00485-1
pmid: 33133514
|
|
|
[28] |
Huang H Y, Liu Y Q, Liao W X, et al. Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy. Nature Communications, 2019, 10(1): 1-15.
doi: 10.1038/s41467-018-07882-8
|
|
|
[29] |
Raimondi G, Gea-Sorlí S, Otero-Mateo M, et al. Inhibition of miR-222 by oncolytic adenovirus-encoded miRNA sponges promotes viral oncolysis and elicits antitumor effects in pancreatic cancer models. Cancers, 2021, 13(13): 3233.
doi: 10.3390/cancers13133233
|
|
|
[30] |
Froechlich G, Caiazza C, Gentile C, et al. Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of Herpes simplex oncolytic virus. Cancers, 2020, 12(11): 3407.
doi: 10.3390/cancers12113407
|
|
|
[31] |
Eriksson E, Milenova I, Wenthe J, et al. Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res, 2017. 23(19): 5846-5857.
doi: 10.1158/1078-0432.CCR-17-0285
pmid: 28536305
|
|
|
[32] |
Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo Gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Research, 2004, 64(9): 3281-3287.
doi: 10.1158/0008-5472.can-03-3911
pmid: 15126371
|
|
|
[33] |
Autio K, Knuuttila A, Kipar A, et al. Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD 40 ligand in laboratory Beagles. Molecular Therapy - Oncolytics, 2014, 1: 14002.
doi: 10.1038/mto.2014.2
|
|
|
[34] |
Kaufman H L. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. Journal of Clinical Investigation, 2005, 115(7): 1903-1912.
doi: 10.1172/JCI24624
pmid: 15937544
|
|
|
[35] |
Wenthe J, Naseri S, Hellström A C, et al. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40. Cancer Gene Therapy, 2020, 27(12): 948-959.
doi: 10.1038/s41417-020-0176-9
|
|
|
[36] |
Wenthe J, Naseri S, Labani-Motlagh A, et al. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy. Cancer Immunology, Immunotherapy, 2021, 70(10): 2851-2865.
doi: 10.1007/s00262-021-02895-7
|
|
|
[37] |
Ylösmäki E, Ylösmäki L, Fusciello M, et al. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform. Molecular Therapy - Oncolytics, 2021, 20: 459-469.
doi: 10.1016/j.omto.2021.02.006
|
|
|
[38] |
Rosen L S, Camidge D R, Khalil D, et al. FORTITUDE: results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro). Journal of Clinical Oncology, 2022, 40(16_suppl): 2559.
doi: 10.1200/JCO.2022.40.16_suppl.2559
|
|
|
[39] |
Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Research, 2017, 77(14): 3894-3907.
doi: 10.1158/0008-5472.CAN-17-0468
pmid: 28566332
|
|
|
[40] |
Chaurasiya S, Fong Y, Warner S G. Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges. Cancers, 2020, 12(6): 1699.
doi: 10.3390/cancers12061699
|
|
|
[41] |
Vilgelm A E, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Frontiers in Immunology, 2019, 10: 333.
doi: 10.3389/fimmu.2019.00333
pmid: 30873179
|
|
|
[42] |
Mgrditchian T, Arakelian T, Paggetti J, et al. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114(44): e9271-e9279.
|
|
|
[43] |
Li J, O’Malley M, Urban J, et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Molecular Therapy, 2011, 19(4): 650-657.
doi: 10.1038/mt.2010.312
pmid: 21266959
|
|
|
[44] |
Li F, Sheng Y Q, Hou W, et al. CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. 2020, 8(1) :e000131.
|
|
|
[45] |
Tian Y M, Xie D Y, Yang L. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2022, 7: 117.
doi: 10.1038/s41392-022-00951-x
pmid: 35387984
|
|
|
[46] |
Qiu Y, Su M X, Liu L Y, et al. Clinical application of cytokines in cancer immunotherapy. Drug Design, Development and Therapy, 2021, 15: 2269-2287.
doi: 10.2147/DDDT.S308578
pmid: 34079226
|
|
|
[47] |
Shiomi A, Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators of Inflammation, 2015, 2015: 1-13.
|
|
|
[48] |
Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. OncoImmunology, 2016, 5(1): e1115641.
doi: 10.1080/2162402X.2015.1115641
|
|
|
[49] |
Kaufman H L, Kim D W, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic Herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Annals of Surgical Oncology, 2010, 17(3): 718-730.
doi: 10.1245/s10434-009-0809-6
pmid: 19915919
|
|
|
[50] |
Kim K J, Moon D, Kong S J, et al., Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. Gene Ther, 2021, 28(3-4): 186-198.
doi: 10.1038/s41434-020-00205-x
|
|
|
[51] |
Lee J H, Roh M S, Lee Y K, et al. Oncolytic and immunostimulatory efficacy of a targeted oncolytic poxvirus expressing human GM-CSF following intravenous administration in a rabbit tumor model. Cancer Gene Therapy, 2010, 17(2): 73-79.
doi: 10.1038/cgt.2009.50
pmid: 19629143
|
|
|
[52] |
Lemay C G, Rintoul J L, Kus A, et al. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine. Molecular Therapy, 2012, 20(9): 1791-1799.
doi: 10.1038/mt.2012.128
pmid: 22760544
|
|
|
[53] |
Robinson M, Li B, Ge Y, et al. Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectors. Journal of Virology, 2009, 83(8): 3450-3462.
doi: 10.1128/JVI.02561-08
pmid: 19193803
|
|
|
[54] |
Kemp V, van den Wollenberg D J M, Camps M G M, et al. Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Therapy, 2019, 26(9): 268-281.
doi: 10.1038/s41417-018-0063-9
|
|
|
[55] |
Konrad M W, Hemstreet G, Hersh E M, et al. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Research, 1990, 50(7): 2009-2017.
pmid: 2317789
|
|
|
[56] |
Liu Z Q, Ge Y, Wang H Y, et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nature Communications, 2018, 9(1): 1-9.
doi: 10.1038/s41467-017-02088-w
|
|
|
[57] |
Koeller J M. Biologic response modifiers: the interferon Alfa experience. American Journal of Hospital Pharmacy, 1989, 46(11_Suppl): S11-S15.
|
|
|
[58] |
Bourgeois-Daigneault M C, Roy D G, Falls T, et al. Oncolytic vesicular stomatitis virus expressing interferon-σ has enhanced therapeutic activity. Molecular Therapy - Oncolytics, 2016, 3: 16001.
doi: 10.1038/mto.2016.1
|
|
|
[59] |
Su C Q, Peng L H, Sham J, et al. Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-γ gene yields efficient antitumor activity in immunodeficient and immunocompetent mice. Molecular Therapy, 2006, 13(5): 918-927.
doi: 10.1016/j.ymthe.2005.12.011
|
|
|
[60] |
Daud A I, Wolchok J D, Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol, 2016, 34(34): 4102-4109.
pmid: 27863197
|
|
|
[61] |
Kelly K R, Espitia C M, Zhao W, et al. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia, 2018, 32(1): 230-233.
doi: 10.1038/leu.2017.272
pmid: 28832023
|
|
|
[62] |
Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. J Clin Oncol, 2018. 36(17): 1658-1667.
doi: 10.1200/JCO.2017.73.7379
pmid: 28981385
|
|
|
[63] |
Moon E K, Wang L C S, Bekdache K, et al. Intra-tumoral delivery of CXCL 11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. OncoImmunology, 2018, 7(3): e1395997.
doi: 10.1080/2162402X.2017.1395997
|
|
|
[64] |
Nishio N, Dotti G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. OncoImmunology, 2015, 4(2): e988098.
doi: 10.4161/21505594.2014.988098
|
|
|
[65] |
Soliman H, Hogue D, Han H, et al. A phase I trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer. Clin Cancer Res, 2021, 27(4): 1012-1018.
doi: 10.1158/1078-0432.CCR-20-3105
pmid: 33219014
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|